title: [Bisphosphonates for malignant bone tumors].
abstract: Bisphosphonates (BPs) are able to prevent, reduce, or delay skeletal complications caused by tumors. Since the introduction of BPs, there has been a marked reduction of skeletal events. Today we can choose from a variety of BPs with different potency, efficacy, dosing, and administration regimens, as well as BPs for different indications. For patients with tumors who have a risk of developing osteoporosis induced by the tumor or antitumor treatment, we should think of prevention. In general, BPs are well tolerated. But there are also side effects: flulike syndrome, arthralgias, or, when administered orally, gastrointestinal symptoms. In a number of cases, the dosing regime must be adjusted according to renal function and baseline creatinine clearance. This paper reviews the current evidence-based use of BPs in solid tumors and the recommendations for treatment.
authors.affiliation: Universitätsklinik für Orthopädie, Medizinische Universität, Wien, Osterreich. gerold.holzer@meduniwien.ac.at
authors.forename: G
authors.initials: G
authors.lastname: Holzer
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D001859:Bone Neoplasms / Q000175:diagnosis* / Q000188:drug therapy*; D004164:Diphosphonates / Q000008:administration & dosage*; D006801:Humans
chemical_list: D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents; D004164:Diphosphonates